Table 4.

DDRs associated therapy and the related drugs in cancer therapeutics.

Therapeutics Target	Drug	Mechanism	Cancer Type	Status	Reference
DDRs	nilotinib	inhibiting the kinase activity of DDR1	colorectal cancer		[216]
	Dasatinib	inhibit DDRs	prostate cancer, glioblastoma, breast cancer, lung cancer, gastric cancer	in clinical trials	[217,218,219,220,221,222,223]
	Nilotinib	inhibit DDRs	colorectal cancer, colon cancer	in clinical trials	[217,224,225,226]
	Imatinib	inhibit DDRs	lung cancer, liver cancer	in clinical trials	[227,228,229,230]
	Ponatinib	inhibit DDRs	lung cancer	in clinical trials	[231,232]
	T4H11-DM4	an antibody-drug conjugate targeting DDR1	colon cancer	awaiting further clinical studies	[233]
	Actinomycin D	an antagonist of the DDR2-collagen interaction	rhabdomyosarcoma, Ewing’s sarcoma, trophoblastic neoplasia, and testicular carcinoma	in clinical application	[234,235]
	LCB 03-0110	inhibiting collagen-induced activation of DDR1 and DDR2 receptors	-	awaiting further clinical studies	[236,237]
	pyrazolo-urea containing compounds 2a, 4a, 4b	inhibit DDR2	-	awaiting further clinical studies	[238]
	7rh	inhibited the kinase activity of DDR1	gastric cancer, nasopharyngeal carcinoma, pancreatic ductal adenocarcinoma, breast cancer, uveal melanoma	in clinical trials	[218,239,240,241,242,243]
	7rj	inhibited the kinase activity of DDR1	-	awaiting further clinical studies	[235]
	DDR1-IN-1	induced a significant inhibitory effect against DDR1	colorectal cancer, lung cancer	awaiting further clinical studies	[232,244,245,246]
	DDR1-IN-2	induced a significant inhibitory effect against DDR1	-	awaiting further clinical studies	[235]
	miR-199a-5p, a targeted delivery of miRNAs	inhibit DDRs	colorectal cancer, renal cancer	awaiting further clinical studies	[247,248,249,250]
	monoclonal antibodies Fab 3E3, 48B3, H-126	inhibit DDRs	ductal breast carcinoma	awaiting further clinical studies	[235,251]